The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
- PMID: 32178772
- PMCID: PMC7232025
- DOI: 10.1016/S2468-1253(19)30408-X
The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Abstract
Background: Gastro-oesophageal reflux disease is a common chronic ailment that causes uncomfortable symptoms and increases the risk of oesophageal adenocarcinoma. We aimed to report the burden of gastro-oesophageal reflux disease in 195 countries and territories between 1990 and 2017, using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017.
Methods: We did a systematic review to identify measurements of the prevalence of gastro-oesophageal reflux disease in geographically defined populations worldwide between 1990 and 2017. These estimates were analysed with DisMod-MR, a Bayesian mixed-effects meta-regression tool that incorporates predictive covariates and adjustments for differences in study design in a geographical cascade of models. Fitted values for broader geographical units inform prior distributions for finer geographical units. Prevalence was estimated for 195 countries and territories. Reports of the frequency and severity of symptoms among individuals with gastro-oesophageal reflux disease were used to estimate the prevalence of cases with no, mild to moderate, or severe to very severe symptoms at a given time; these estimates were multiplied by disability weights to estimate years lived with disability (YLD).
Findings: Data to estimate gastro-oesophageal reflux disease burden were scant, totalling 144 location-years (unique measurements from a year and location, regardless of whether a study reported them alongside measurements for other locations or years) of prevalence data. These came from six (86%) of seven GBD super-regions, 11 (52%) of 21 GBD regions, and 39 (20%) of 195 countries and territories. Mean estimates of age-standardised prevalence for all locations in 2017 ranged from 4408 cases per 100 000 population to 14 035 cases per 100 000 population. Age-standardised prevalence was highest (>11 000 cases per 100 000 population) in the USA, Italy, Greece, New Zealand, and several countries in Latin America and the Caribbean, north Africa and the Middle East, and eastern Europe; it was lowest (<7000 cases per 100 000 population) in the high-income Asia Pacific, east Asia, Iceland, France, Denmark, and Switzerland. Global prevalence peaked at ages 75-79 years, at 18 820 (95% uncertainty interval [95% UI] 13 770-24 000) cases per 100 000 population. Global age-standardised prevalence was stable between 1990 and 2017 (8791 [95% UI 7772-9834] cases per 100 000 population in 1990 and 8819 [7781-9863] cases per 100 000 population in 2017, percentage change 0·3% [-0·3 to 0·9]), but all-age prevalence increased by 18·1% (15·6-20·4) between 1990 and 2017, from 7859 (6905-8851) cases per 100 000 population in 1990 to 9283 (8189-10 400) cases per 100 000 population in 2017. YLDs increased by 67·1% (95% UI 63·5-70·3) between 1990 and 2017, from 3·60 million (1·93-6·12) in 1990 to 6·01 million (3·22-10·19) in 2017.
Interpretation: Gastro-oesophageal reflux disease is common worldwide, although less so in much of eastern Asia. The stability of our global age-standardised prevalence estimates over time suggests that the epidemiology of the disease has not changed, but the estimates of all-age prevalence and YLDs, which increased between 1990 and 2017, suggest that the burden of gastro-oesophageal reflux disease is nonetheless increasing as a result of ageing and population growth.
Funding: Bill & Melinda Gates Foundation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Figures




Comment in
-
The global burden of gastro-oesophageal reflux disease: more than just heartburn and regurgitation.Lancet Gastroenterol Hepatol. 2020 Jun;5(6):519-521. doi: 10.1016/S2468-1253(20)30002-9. Epub 2020 Mar 13. Lancet Gastroenterol Hepatol. 2020. PMID: 32178771 No abstract available.
-
A global perspective on oesophageal cancer: two diseases in one.Lancet Gastroenterol Hepatol. 2020 Jun;5(6):521-522. doi: 10.1016/S2468-1253(20)30047-9. Epub 2020 Apr 1. Lancet Gastroenterol Hepatol. 2020. PMID: 32246940 No abstract available.
Similar articles
-
The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet Gastroenterol Hepatol. 2020 Jun;5(6):582-597. doi: 10.1016/S2468-1253(20)30007-8. Epub 2020 Apr 1. Lancet Gastroenterol Hepatol. 2020. PMID: 32246941 Free PMC article.
-
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet. 2018 Nov 10;392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8. Lancet. 2018. PMID: 30496104 Free PMC article.
-
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.Lancet. 2017 Sep 16;390(10100):1211-1259. doi: 10.1016/S0140-6736(17)32154-2. Lancet. 2017. PMID: 28919117 Free PMC article.
-
Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.Lancet Psychiatry. 2022 Feb;9(2):137-150. doi: 10.1016/S2215-0366(21)00395-3. Epub 2022 Jan 10. Lancet Psychiatry. 2022. PMID: 35026139 Free PMC article.
-
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.Lancet. 2015 Aug 22;386(9995):743-800. doi: 10.1016/S0140-6736(15)60692-4. Epub 2015 Jun 7. Lancet. 2015. PMID: 26063472 Free PMC article. Review.
Cited by
-
Multicentric short term and safety study of ineffective esophageal motility patients treated with RefluxStop device.Sci Rep. 2024 Jul 4;14(1):15425. doi: 10.1038/s41598-024-65751-5. Sci Rep. 2024. PMID: 38965324 Free PMC article.
-
Prescription Appropriateness of Drugs for Peptic Ulcer and Gastro-Esophageal Reflux Disease: Baseline Assessment in the LAPTOP-PPI Cluster Randomized Trial.Front Pharmacol. 2022 Mar 28;13:803809. doi: 10.3389/fphar.2022.803809. eCollection 2022. Front Pharmacol. 2022. PMID: 35418868 Free PMC article.
-
Side effects of drug treatments for gastro-oesophageal reflux disease: current controversies.Frontline Gastroenterol. 2020 Aug 12;13(1):45-49. doi: 10.1136/flgastro-2019-101386. eCollection 2022. Frontline Gastroenterol. 2020. PMID: 34966532 Free PMC article.
-
Antireflux mucosectomy (ARMS) and antireflux mucosal ablation (ARMA) for gastroesophageal reflux disease: a systematic review and meta-analysis.Endosc Int Open. 2021 Nov 12;9(11):E1740-E1751. doi: 10.1055/a-1552-3239. eCollection 2021 Nov. Endosc Int Open. 2021. PMID: 34790538 Free PMC article. Review.
-
Potassium-Competitive Acid Blockers and Gastroesophageal Reflux Disease.Gastroenterol Hepatol (N Y). 2023 May;19(5):295-298. Gastroenterol Hepatol (N Y). 2023. PMID: 37799455 Free PMC article. No abstract available.
References
-
- Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–1920. - PubMed
-
- Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol. 2006;101:2619–2628. - PubMed
-
- Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143:199–211. - PubMed
-
- Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67:430–440. - PubMed
-
- Becher A, Dent J. Systematic review: ageing and gastro-oesophageal reflux disease symptoms, oesophageal function and reflux oesophagitis. Aliment Pharmacol Ther. 2011;33:442–454. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical